{"id":"W4386697187","doi":"10.1016/j.clml.2023.09.003","title":"Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Pharmaceuticals; Janssen Scientific Affairs; Regeneron Pharmaceuticals; Celgene; Array BioPharma; Alnylam Pharmaceuticals; National Comprehensive Cancer Network; Sanofi; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Hazard ratio; Medicine; Lenalidomide; Daratumumab; Internal medicine; Multiple myeloma; Oncology; Progression-free survival; Population; Proportional hazards model; Confidence interval; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001897771,0.0005837235,0.00189807,0.0004153857,0.0001675585,0.00004030633,0.0003949497,0.0002500666,0.00002872774],"category_scores_gemma":[0.002983938,0.0003986854,0.0001900722,0.001598643,0.0004093767,0.0002586348,0.000200686,0.0004280529,0.000031722],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004590541,"about_ca_system_score_gemma":0.0009132182,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004848251,"about_ca_topic_score_gemma":0.001127389,"domain_scores_codex":[0.9940795,0.0007215474,0.001606645,0.001094143,0.001657602,0.0008406036],"domain_scores_gemma":[0.9941743,0.003063383,0.0005182357,0.001144844,0.0004678256,0.0006314272],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.03761747,0.003297346,0.8019742,0.0007443742,0.0005207388,0.001461205,0.0001919424,0.000003430954,0.00002141338,0.00001407867,0.0004735424,0.1536803],"study_design_scores_gemma":[0.1669475,0.00805724,0.820308,0.003001202,0.0003935585,0.00001699331,0.0001746323,0.0004256027,0.0001378941,0.0000124959,0.0001835506,0.0003412784],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9924803,0.001318746,0.00001359452,0.0004182532,0.000209391,0.005047663,0.0001675129,0.0001497841,0.0001947282],"genre_scores_gemma":[0.9942983,0.003206661,0.0007611868,0.00009994588,0.00007418916,0.0006051878,0.0008008574,0.00009355098,0.00006015471],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.153339,"threshold_uncertainty_score":0.9998465,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04650279661337501,"score_gpt":0.3550013715950573,"score_spread":0.3084985749816823,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}